Abstract

Pulmonary fibrosis (PF) is a pathological change caused by repeated injuries and repair dysfunction of the alveolar epithelium. Our previous study revealed that the residues Asn3 and Asn4 of peptide DR8 (DHNNPQIR-NH 2 ) could be modified to improve stability and antifibrotic activity, and the unnatural hydrophobic amino acids α -(4-pentenyl)-Ala and d -Ala were considered in this study. DR3penA (DH α -(4-pentenyl)-ANPQIR-NH 2 ) was verified to have a longer half-life in serum and to significantly inhibit oxidative damage, epithelial–mesenchymal transition (EMT) and fibrogenesis in vitro and in vivo . Moreover, DR3penA has a dosage advantage over pirfenidone through the conversion of drug bioavailability under different routes of administration. A mechanistic study revealed that DR3penA increased the expression of aquaporin 5 (AQP5) by inhibiting the upregulation of miR-23b-5p and the mitogen-activated protein kinase (MAPK) pathway, indicating that DR3penA may alleviate PF by regulating MAPK/miR-23b-5p/AQP5. Safety evaluation showed that DR3penA is a peptide drug without obvious toxicity or acute side effects and has significantly improved safety compared to DR8. Thus, our findings suggest that DR3penA, as a novel and low-toxic peptide, has the potential to be a leading compound for PF therapy, which provides a foundation for the development of peptide drugs for fibrosis-related diseases.